Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.66 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23538057 | 0.88 | EGFR (0.78) | EGFRERBB2ERBB4 | |
| SCHEMBL23538059 | 0.88 | EGFR (0.78) | EGFRERBB2ERBB4 | |
| SCHEMBL5564412 | 0.86 | EGFR (0.76) | EGFRERBB2ERBB4 | |
| SCHEMBL3434524 | 0.85 | EGFR (0.75) | EGFRERBB2ERBB4 | |
| SCHEMBL3420740 | 0.85 | EGFR (0.85) | EGFRERBB2 | |
| SCHEMBL16606117 | 0.84 | EGFR (1.00) | EGFRERBB2ERBB4 | |
| SCHEMBL23537954 | 0.84 | EGFR (0.72) | EGFRERBB2ERBB4 | |
| SCHEMBL23537578 | 0.83 | EGFR (0.72) | EGFRERBB2ERBB4 | |
| SCHEMBL23537792 | 0.82 | EGFR (0.70) | EGFRERBB2ERBB4 | |
| SCHEMBL23537790 | 0.82 | EGFR (0.70) | EGFRERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167492-B1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI SCIENCE CO LTD (KR) | 2015-10-14 | — | — | EP | claimed |
| US-8188102-B2 | Amide derivative for inhibiting the growth of cancer cells | HANMI HOLDINGS CO., LTD. (KR) | 2012-05-29 | — | — | US | claimed |
| US-20100179120-A1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2010-07-15 | — | — | US | claimed |
| EP-2167492-A2 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | Hanmi Pharm. Co., Ltd. (KR) | 2010-03-31 | — | — | EP | claimed |
| WO-2008150118-A2 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2008-12-11 | — | — | WO | claimed |
| EP-2167492-B1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI SCIENCE CO LTD (KR) | 2015-10-14 | — | — | EP | disclosed |
| US-8188102-B2 | Amide derivative for inhibiting the growth of cancer cells | HANMI HOLDINGS CO., LTD. (KR) | 2012-05-29 | — | — | US | disclosed |
| US-8188102-B2 | Amide derivative for inhibiting the growth of cancer cells | HANMI HOLDINGS CO., LTD. (KR) | 2012-05-29 | — | — | US | disclosed |
| US-8188102-B2 | Amide derivative for inhibiting the growth of cancer cells | HANMI HOLDINGS CO., LTD. (KR) | 2012-05-29 | — | — | US | disclosed |
| US-20100179120-A1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2010-07-15 | — | — | US | disclosed |
| US-20100179120-A1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2010-07-15 | — | — | US | disclosed |
| US-20100179120-A1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179120-A1 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885ERBB4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.